For the purpose of promoting collaborative innovation of industry, academia and research, and promoting the R&D and industrial translation of innovative polypeptide drugs, on the afternoon of April 19, Shenzhen Bay Laboratory, Shenzhen Bay Laboratory Pingshan Translational Medicine Center ("Pingshan Center") and Hybio Pharmaceuticals jointly held a strategic cooperation signing and opening ceremony in Shenzhen for the establishment of the "Joint Innovation Center for the Industrial Translation of Innovative Polypeptide Drugs" to actively promote the industrialization of research and innovation achievements.
Academician Wu Yun-Dong, Vice Executive Director of Shenzhen Bay Laboratory, Tu Huan, Vice Director of the Laboratory and Director of the Pingshan Center, together with Zeng Shaogui, President of Hybio Pharmaceutical, and Yu Pinxiang, Executive President of Hybio Pharmaceutical, unveiled for the "Joint Innovation Center for the Industrial Translation of Polypeptide Innovative Drugs".
Jointly Build a Translational Platform for the Polypeptide Innovative Drug Achievements
Shenzhen Bay Laboratory and Pingshan Center have strong research capabilities in the fields of polypeptide oncology drugs, polypeptide duplex chemicals (PDCs) and polypeptide oncology vaccines. Hybio Pharmaceutical is a leading pharmaceutical company with over 20 years of experience in polypeptide research and development, and has deep technical experience in the industry. The collaboration will provide a strong driving force for the development and upgrade of the polypeptide industry, and provide strong scientific and technological support for the development of the bio-pharmaceutical industry in Shenzhen.
According to the agreement, the Joint Innovation center for the Industrial Translation of Innovative Polypeptide Drugs (Joint Innovation center for Polypeptides) will be established to collaborate on the research of anti-infective and anti-tumour polypeptide drugs and polypeptide vaccines. Through the Joint Innovation center for Polypeptides, high quality candidate polypeptide drug researches will be carried out and projects will be implemented to jointly develop new polypeptide drugs with excellent drug properties and efficacy, and to promote the research and development of innovative polypeptide drugs as well as the industrialization of the achievements.
Promote the Innovative Development of Bio-Pharmaceutical Industry in Shenzhen
At the signing ceremony, Academician Wu Yun-Dong affirmed the achievements made by Hybio Pharmaceutical over the years in the field of polypeptides. He said that in recent years, polypeptide drugs have become a hot spot for drug research and development, and China's polypeptide drug industry is developing rapidly with a very broad market prospect. Shenzhen Bay Laboratory has also conducted research in the field of polypeptide drugs. The collaboration with Hybio Pharmaceutical would combine the laboratory's strengths in scientific research and results translations with Hybio's R&D and industrial strengths in the polypeptide field to provide in-depth cooperation in new drug development, platform building and achievement translations to effectively accelerate the transformation of the industry, so as to achieve win-win cooperation and boost the innovative development of the polypeptide industry.
Zeng Shaogui, President of Hybio Pharmaceutical, said that the Shenzhen Bay Laboratory is one of the second batch of laboratories in Guangdong Province, and the Pingshan center is an important window for research and translation and a pioneer demonstration base for Shenzhen Bay Laboratory; Hybio Pharmaceutical is a national high-tech enterprise specialising in the research and development, production and sales of polypeptide drugs, and this cooperation will definitely collide with "sparks" in the field of innovative polypeptide drug development and industrial translation, and provide a driving force for the development of the polypeptide industry. Hybio Pharmaceutical will continue to increase investment in innovative research and development, give full play to the strength of polypeptide drug technology research and development innovation, industrialization to further enhance the efficiency of industrial translation of innovative drug achievements in the polypeptide industry, and work together to make positive contributions to the development of the bio-pharmaceutical industry in Shenzhen.
